Search Results - "Sonobe, Yukiko"

Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancer by Ohashi, Kana, Nishito, Yukari, Fukuda, Hironori, Sadahiro, Ryoichi, Yoshida, Yukihiro, Watanabe, Shun-ichi, Motoi, Noriko, Sonobe, Yukiko, Mizuno, Hideaki, Tsunoda, Hiroyuki, Tatsumi, Koichiro, Suzuki, Takuji, Ochiai, Atsushi, Aoki, Kazunori

“…Inflammatory factors in the peripheral blood, such as the C-reactive protein level and neutrophil-to-lymphocyte ratio (NLR), are prognostic markers in multiple…”
Get full text

MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor by Aida, Satoshi, Sonobe, Yukiko, Tanimura, Hiromi, Oikawa, Nobuhiro, Yuhki, Munehiro, Sakamoto, Hiroshi, Mizuno, Takakazu

“…Microphthalmia-associated transcription factor (MITF) is expressed in melanomas and has a critical role in melanocyte development and transformation. Because…”
Get full text

An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors by Ishiguro, Takahiro, Sano, Yuji, Komatsu, Shun-Ichiro, Kamata-Sakurai, Mika, Kaneko, Akihisa, Kinoshita, Yasuko, Shiraiwa, Hirotake, Azuma, Yumiko, Tsunenari, Toshiaki, Kayukawa, Yoko, Sonobe, Yukiko, Ono, Natsuki, Sakata, Kiyoaki, Fujii, Toshihiko, Miyazaki, Yoko, Noguchi, Mizuho, Endo, Mika, Harada, Asako, Frings, Werner, Fujii, Etsuko, Nanba, Eitaro, Narita, Atsushi, Sakamoto, Akihisa, Wakabayashi, Tetsuya, Konishi, Hiroko, Segawa, Hiroaki, Igawa, Tomoyuki, Tsushima, Takashi, Mutoh, Hironori, Nishito, Yukari, Takahashi, Mina, Stewart, Lorraine, ElGabry, Ehab, Kawabe, Yoshiki, Ishigai, Masaki, Chiba, Shuichi, Aoki, Masahiro, Hattori, Kunihiro, Nezu, Junichi

“…Cancer care is being revolutionized by immunotherapies such as immune checkpoint inhibitors, engineered T cell transfer, and cell vaccines. The bispecific T…”
Get more information

MITF suppression by CH5552074 inhibits cell growth in melanoma cells by Aida, Satoshi, Sonobe, Yukiko, Yuhki, Munehiro, Sakata, Kiyoaki, Fujii, Toshihiko, Sakamoto, Hiroshi, Mizuno, Takakazu

“…Purpose Although treatment of melanoma with BRAF inhibitors and immune checkpoint inhibitors achieves a high response rate, a subset of melanoma patients with…”
Get full text

Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments by Fukuda, Hironori, Arai, Kosuke, Mizuno, Hideaki, Nishito, Yukari, Motoi, Noriko, Arai, Yasuhito, Hiraoka, Nobuyoshi, Shibata, Tatsuhiro, Sonobe, Yukiko, Kayukawa, Yoko, Hashimoto, Eri, Takahashi, Mina, Fujii, Etsuko, Maruyama, Toru, Kuwabara, Kenta, Nishizawa, Takashi, Mizoguchi, Yukihiro, Yoshida, Yukihiro, Watanabe, Shun‐ichi, Yamashita, Makiko, Kitano, Shigehisa, Sakamoto, Hiromi, Nagata, Yuki, Mitsumori, Risa, Ozaki, Kouichi, Niida, Shumpei, Kanai, Yae, Hirayama, Akiyoshi, Soga, Tomoyoshi, Tsukada, Keisuke, Yabuki, Nami, Shimada, Mei, Kitazawa, Takehisa, Natori, Osamu, Sawada, Noriaki, Kato, Atsuhiko, Yoshida, Teruhiko, Yasuda, Kazuki, Ochiai, Atsushi, Tsunoda, Hiroyuki, Aoki, Kazunori

“…Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non‐small‐cell lung cancer (NSCLC). Transcriptome analysis shows…”
Get full text

Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations by Aoki, Kazunori, Nishito, Yukari, Motoi, Noriko, Arai, Yasuhito, Hiraoka, Nobuyoshi, Shibata, Tatsuhiro, Sonobe, Yukiko, Kayukawa, Yoko, Hashimoto, Eri, Takahashi, Mina, Fujii, Etsuko, Nishizawa, Takashi, Fukuda, Hironori, Ohashi, Kana, Arai, Kosuke, Mizoguchi, Yukihiro, Yoshida, Yukihiro, Watanabe, Shun-Ichi, Yamashita, Makiko, Kitano, Shigehisa, Sakamoto, Hiromi, Nagata, Yuki, Mitsumori, Risa, Ozaki, Kouichi, Niida, Shumpei, Kanai, Yae, Hirayama, Akiyoshi, Soga, Tomoyoshi, Maruyama, Toru, Tsukada, Keisuke, Yabuki, Nami, Shimada, Mei, Kitazawa, Takehisa, Natori, Osamu, Sawada, Noriaki, Kato, Atsuhiko, Yoshida, Teruhiko, Yasuda, Kazuki, Mizuno, Hideaki, Tsunoda, Hiroyuki, Ochiai, Atsushi

“…Resistance to immune checkpoint blockade remains challenging in patients with non-small cell lung cancer (NSCLC). Tumor-infiltrating leukocyte (TIL) quantity,…”
Get full text